Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' BOKEMEYER C' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 214 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Dittmann, H; Sokler, M; Kollmannsberger, C; Dohmen, BM; Baumann, C; Kopp, A; Bares, R; Claussen, CD; Kanz, L; Bokemeyer, C
      Comparison of (18)FDG-PET with CT scans in the evaluation of patients withresidual and recurrent Hodgkin's lymphoma

      ONCOLOGY REPORTS
    2. Kuczyk, MA; Bokemeyer, C; Hartmann, J; Schubach, J; Walter, C; Machtens, S; Knuchel, R; Kollmannsberger, C; Jonas, U; Serth, J
      Predictive value of altered p27(Kip1) and p21(WAF/Cip1) protein expressionfor the clinical prognosis of patients with localized prostate cancer

      ONCOLOGY REPORTS
    3. Kolb, G; Bokemeyer, C
      The old cancer patient

      ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE
    4. Kohne, CH; Grothey, A; Bokemeyer, C; Bontke, N; Aapro, M
      Chemotherapy in elderly patients with colorectal cancer

      ANNALS OF ONCOLOGY
    5. Hartmann, JT; Einhorn, L; Nichols, CR; Droz, JP; Horwich, A; Gerl, A; Fossa, SD; Beyer, J; Pont, J; Schmoll, HJ; Kanz, L; Bokemeyer, C
      Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis

      JOURNAL OF CLINICAL ONCOLOGY
    6. De Santis, M; Bokemeyer, C; Becherer, A; Stoiber, F; Oechsle, K; Kletter, K; Dohmen, BM; Dittrich, C; Pont, J
      Predictive impact of 2-(18)fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma

      JOURNAL OF CLINICAL ONCOLOGY
    7. Bokemeyer, C; Gillis, AJM; Pompe, K; Mayer, F; Metzner, B; Schleucher, N; Schleicher, J; Pflugrad-Jauch, G; Oosterhuis, JW; Kanz, L; Looijenga, LHJ
      Clinical impact of germ cell tumor cells in apheresis products of patientsreceiving high-dose chemotherapy

      JOURNAL OF CLINICAL ONCOLOGY
    8. Fizazi, K; Tjulandin, S; Salvioni, R; Germa-Lluch, JR; Bouzy, J; Ragan, D; Bokemeyer, C; Gerl, A; Flechon, A; de Bono, JS; Stenning, S; Horwich, A; Pont, J; Albers, P; De Giorgi, U; Bower, M; Bulanov, A; Pizzocaro, G; Aparicio, J; Nichols, CR; Theodore, C; Hartmann, JT; Schmoll, HJ; Kaye, SB; Culine, S; Droz, JP; Mahe, C
      Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy-results from an international study group

      JOURNAL OF CLINICAL ONCOLOGY
    9. Rick, O; Bokemeyer, C; Beyer, J; Hartmann, JT; Schwella, N; Kingreen, D; Neureither, S; Metzner, B; Casper, J; Wandt, H; Hartmann, F; Schmoll, HJ; Derigs, G; Gerl, A; Berdel, WE; Kanz, L; Siegert, W
      Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer

      JOURNAL OF CLINICAL ONCOLOGY
    10. Bokemeyer, C
      Chemotherapy for urogenital malignancies

      WORLD JOURNAL OF UROLOGY
    11. Beyer, J; Rick, O; Siegert, W; Bokemeyer, C
      Salvage chemotherapy in relapsed germ cell tumors

      WORLD JOURNAL OF UROLOGY
    12. Kollmannsberger, C; Mayer, F; Kuczyk, M; Kanz, L; Bokemeyer, C
      Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy

      WORLD JOURNAL OF UROLOGY
    13. Bokemeyer, C; Kolb, G
      The situation of elderly cancer patients

      ONKOLOGIE
    14. Genvresse, I; Wedding, U; Bokemeyer, C; Spath-Schwalbe, E
      Treatment of multiple myeloma in the elderly: Consensus of the cooperativegroup of geriatric oncology of the DGHO and DGG

      ONKOLOGIE
    15. Buntzel, J; Bokemeyer, C; Wagner, W
      Recommendations of the Working Group 'Supportive Massnahmen in der Onkologie' concerning the clinical use of cytoprotectives

      ONKOLOGIE
    16. Honecker, F; Wedding, U; Kolb, G; Bokemeyer, C
      Chemotherapy in colorectal cancer - Which therapy is justified in elderly patients?

      ONKOLOGIE
    17. Machtens, S; Serth, J; Bokemeyer, C; Bathke, W; Minssen, A; Kollmannsberger, C; Hartmann, J; Knuchel, R; Kondo, M; Jonas, U; Kuczyk, M
      Expression of the p53 and maspin protein in primary prostate cancer: Correlation with clinical features

      INTERNATIONAL JOURNAL OF CANCER
    18. Bokemeyer, C; Droz, JP; Horwich, A; Gerl, A; Fossa, SD; Beyer, J; Pont, J; Schmoll, HJ; Kanz, L; Einhorn, L; Nichols, CR; Hartmann, JT
      Extragonadal seminoma - An international multicenter analysis of prognostic factors and long term treatment outcome

      CANCER
    19. Hartmann, JT; von Vangerow, A; Fels, LM; Knop, S; Stolte, H; Kanz, L; Bokemeyer, C
      A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation

      BRITISH JOURNAL OF CANCER
    20. Hartmann, JT; Fossa, SD; Nichols, CR; Droz, JP; Horwich, A; Gerl, A; Beyer, J; Pont, J; Fizazi, K; Hecker, H; Kanz, L; Einhorn, L; Bokemeyer, C
      Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    21. Kollmannsberger, C; Gerl, A; Schleucher, N; Beyer, J; Kuczyk, M; Rick, O; Gasper, J; Sosada, M; Rie, C; Kanz, L; Bokemeyer, C
      Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer

      ANTI-CANCER DRUGS
    22. Hartmann, JT; Knop, S; Fels, LM; van Vangerow, A; Stolte, H; Kanz, L; Bokemeyer, C
      The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors

      ANTI-CANCER DRUGS
    23. Bethge, W; Guggenberger, D; Bamberg, M; Kanz, L; Bokemeyer, C
      Thyroid toxicity of treatment for Hodgkin's disease

      ANNALS OF HEMATOLOGY
    24. Kollmannsberger, C; Nichols, C; Meisner, C; Mayer, F; Kanz, L; Bokemeyer, C
      Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: An explorative analysis using cart modeling

      ANNALS OF ONCOLOGY
    25. Kollmannsberger, C; Nichols, C; Bamberg, M; Hartmann, JT; Schleucher, N; Beyer, J; Schoffski, P; Derigs, G; Ruther, U; Bohlke, I; Schmoll, HJ; Kanz, L; Bokemeyer, C
      First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases

      ANNALS OF ONCOLOGY
    26. Bokemeyer, C; Kollmannsberger, C; Hartmann, JT; Kanz, L
      Follow up after primary treatment: curable diseases treated non-surgically

      ANNALS OF ONCOLOGY
    27. Bokemeyer, C; Hartmann, JT; Mayer, F; Bohlke, I; Kanz, L; von Pawel, J; Derigs, G; Schroder, M
      UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors

      ONCOLOGY-NEW YORK
    28. Kollmannsberger, C; Bokemeyer, C
      Therapy-related leukemia following high-dose chemotherapy: Compensating for the benefit?

      ONKOLOGIE
    29. Bokemeyer, C
      Wilsede School for Oncology and Hematology: Reviewing the years 1989-1999

      ONKOLOGIE
    30. Bokemeyer, C
      Irinotecan - Clinical progress in the second-line therapy of advanced colorectal cancer

      ONKOLOGIE
    31. Einsele, H; Hebart, H; Kauffman-Schneider, C; Sinzger, C; Jahn, G; Bader, P; Klingebiel, T; Dietz, K; Loffler, J; Bokemeyer, C; Muller, CA; Kanz, L
      Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

      BONE MARROW TRANSPLANTATION
    32. Hartmann, JT; Fels, LM; Franzke, A; Knop, S; Renn, M; Maess, B; Panagiotou, P; Lampe, H; Kanz, L; Stolte, H; Bokemeyer, C
      Comparative study of the acute nephrotoxicity from standard dose cisplatin+/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide

      ANTICANCER RESEARCH
    33. Hartmann, JT; Kanz, L; Bokemeyer, C
      Phase II study of continuous 120-hour- infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma

      ANTICANCER RESEARCH
    34. Souchon, R; Krege, S; Schmoll, HJ; Albers, P; Beyer, J; Bokemeyer, C; Classen, J; Dieckmann, KP; Hartmann, M; Heidenreich, A; Holtl, W; Kliesch, S; Kohrmann, KU; Kuczyk, M; Schmidberger, H; Weinknecht, S; Winter, E; Wittekind, C; Bamberg, M
      Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors. Results of an update conference based on evidence-based medicine (EBM)

      STRAHLENTHERAPIE UND ONKOLOGIE
    35. Hartmann, JT; Fels, LM; Knop, S; Stolte, H; Kanz, L; Bokemeyer, C
      A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors

      INVESTIGATIONAL NEW DRUGS
    36. Hartmann, JT; Bokemeyer, C
      Diarrhea and constipation

      SUPPORTIVE CARE IN CANCER PATIENTS: RECENT DEVELOPMENTS
    37. Hartmann, JT; Nichols, CR; Droz, JP; Horwich, A; Gerl, A; Fossa, SD; Beyer, J; Pont, J; Einhorn, L; Kanz, L; Bokemeyer, C
      The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors

      CANCER
    38. Kollmannsberger, C; Quietzsch, D; Haag, C; Lingenfelser, T; Schroeder, M; Hartmann, JT; Baronius, W; Hempel, V; Clemens, M; Kanz, L; Bokemeyer, C
      A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

      BRITISH JOURNAL OF CANCER
    39. Roelofs, H; Mostert, MC; Pompe, K; Zafarana, G; van Oorschot, M; van Gurp, RJHLM; Gillis, AJM; Stoop, H; Beverloo, B; Oosterhuis, JW; Bokemeyer, C; Looijenga, LHJ
      Restricted 12p amplification and RAS mutation in human germ cell tumors ofthe adult testis

      AMERICAN JOURNAL OF PATHOLOGY
    40. Hartmann, JT; Nichols, CR; Droz, JP; Horwich, A; Gerl, A; Fossa, SD; Beyer, J; Pont, J; Fizazi, K; Einhorn, L; Kanz, L; Bokemeyer, C
      Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    41. Kollmannsberger, C; Kuzcyk, M; Mayer, F; Hartmann, JT; Kanz, L; Bokemeyer, C
      Late toxicity following curative treatment of testicular cancer

      SEMINARS IN SURGICAL ONCOLOGY
    42. Kuczyk, MA; Machtens, S; Bokemeyer, C; Hradil, K; Macheel, I; Jetscho, V; Hartmann, J; Thon, WF; Jonas, U; Serth, J
      Prognostic value of p27(Kip1) and p21(WAF/Cip) protein expression in muscle invasive bladder cancer

      ONCOLOGY REPORTS
    43. Serth, J; Kuczyk, M; Machtens, S; Bokemeyer, C; Herrmann, R; Hartmann, J; Knuchel, R; Jonas, U
      Analysis of the cyclin-dependent kinase inhibitor p27(Kip1) in muscle invasive bladder cancer

      ONCOLOGY REPORTS
    44. Hartmann, JT; Quietzsch, D; Daikeler, T; Kollmannsberger, C; Mayer, F; Kanz, L; Bokemeyer, C
      Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer

      ANTI-CANCER DRUGS
    45. Kollmannsberger, C; Brugger, W; Hartmann, JT; Maurer, F; Bohm, P; Kanz, L; Bokemeyer, C
      Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma

      ANTI-CANCER DRUGS
    46. Kollmannsberger, C; Pressler, H; Mayer, F; Kanz, L; Bokemeyer, C
      Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: Induction of remission by the monoclonal antibody Trastuzumab

      ANNALS OF ONCOLOGY
    47. Bokemeyer, C; Hartmann, JT; Kollmannsberger, C; Mayer, F; Kanz, L
      UFT/calcium folinate plus weekly paclitaxel for solid tumors

      ONCOLOGY-NEW YORK
    48. Bokemeyer, C; Gerl, A; Schoffski, P; Harstrick, A; Niederle, N; Beyer, J; Casper, J; Schmoll, HJ; Kanz, L
      Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer

      JOURNAL OF CLINICAL ONCOLOGY
    49. Bokemeyer, C; Kollmannsberger, C; Meisner, C; Harstrick, A; Beyer, J; Metzner, B; Hartmann, JT; Schmoll, HL; Einhorn, L; Kanz, L; Nichols, C
      First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis

      JOURNAL OF CLINICAL ONCOLOGY
    50. Hartmann, JT; Kuczyk, MA; Kollmannsberger, C; Kanz, L; Bokemeyer, C
      Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer

      WORLD JOURNAL OF UROLOGY
    51. Kuczyk, M; Serth, J; Bokemeyer, C; Machtens, S; Schwede, J; Herrmann, R; Paeslack, U; Truss, MC; Knuchel, R; Jonas, U
      The need for microdissectional tumor cell preparation during the moleculargenetic analysis of prostate cancer

      WORLD JOURNAL OF UROLOGY
    52. Hebart, H; Bokemeyer, C; Loffler, J; Schumacher, U; Kanz, L; Einsele, H
      Management of invasive fungal infections in oncological patients

      ONKOLOGIE
    53. Machtens, S; Kuczyk, M; Becker, AJ; Bokemeyer, C; Serth, J; Jonas, U
      New aspects on the identification of genetic alterations and prognostically important biological parameters in renal cell cancer

      UROLOGE-AUSGABE A
    54. Hartmann, JT; Bokemeyer, C
      Chemotherapy for renal cell carcinoma

      ANTICANCER RESEARCH
    55. Kollmannsberger, C; Mross, K; Jakob, A; Kanz, L; Bokemeyer, C
      Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience

      ONCOLOGY
    56. Bokemeyer, C; Bamberg, M; Albers, J; Schmoll, HJ; Weissbach, L
      UICC Symposium on Testicular Cancer: Guidelines for Standard Care and Future Prospects

      INTERNATIONAL JOURNAL OF CANCER
    57. Bokemeyer, C; Kollmannsberger, C; Harstrick, A; Beyer, J; Gerl, A; Casper, J; Metzner, B; Hartmann, JT; Schmoll, HJ; Kanz, L
      Treatment of patients with cisplatin-refractory testicular germ-cell cancer

      INTERNATIONAL JOURNAL OF CANCER
    58. Kollmannsberger, C; Hartmann, JT; Kanz, L; Bokemeyer, C
      Therapy-related malignancies following treatment of germ cell cancer

      INTERNATIONAL JOURNAL OF CANCER
    59. Hartmann, JT; Kollmannsberger, C; Kanz, L; Bokemeyer, C
      Platinum organ toxicity and possible prevention in patients with testicular cancer

      INTERNATIONAL JOURNAL OF CANCER
    60. Hartmann, JT; Kanz, L; Bokemeyer, C
      Diagnosis and treatment of patients with testicular germ cell cancer

      DRUGS
    61. Fossa, SD; Bokemeyer, C; Gerl, A; Culine, S; Jones, WG; Mead, GM; Germa-Luch, JR; Pont, J; Schmoll, HJ; Tjulandin, S
      Treatment outcome of patients with brain metastases from malignant germ cell tumors

      CANCER
    62. Kuczyk, M; Machtens, S; Hradil, K; Schubach, J; Christian, W; Knuchel, R; Hartmann, J; Bokemeyer, C; Jonas, U; Serth, J
      Predictive value of decreased p27(Kip1) protein expression for the recurrence-free and long-term survival of prostate cancer patients

      BRITISH JOURNAL OF CANCER
    63. Hartmann, JT; Albrecht, C; Schmoll, HJ; Kuczyk, MA; Kollmannsberger, C; Bokemeyer, C
      Long-term effects on sexual function and fertility after treatment of testicular cancer

      BRITISH JOURNAL OF CANCER
    64. Lipp, HP; Bokemeyer, C
      Clinical pharmacokinetics of cytostatic drugs: Efficacy and toxicity

      ANTICANCER DRUG TOXICITY
    65. Bokemeyer, C; Hartmann, JT
      Oral and gastrointestinal toxicity

      ANTICANCER DRUG TOXICITY
    66. Niedermeyer, J; Fabel, H; Bokemeyer, C; Lipp, HP
      Pulmonary toxicity of chemotherapeutic agents

      ANTICANCER DRUG TOXICITY
    67. Bokemeyer, C; Kollmannsberger, C
      Secondary malignancies

      ANTICANCER DRUG TOXICITY
    68. KUCZYK MA; SERTH J; BOKEMEYER C; SCHWEDE J; HERRMANN R; MACHTENS S; GRUNEWALD V; HOFNER K; JONAS U
      THE MXI1 TUMOR-SUPPRESSOR GENE IS NOT MUTATED IN PRIMARY PROSTATE-CANCER

      Oncology Reports
    69. KUCZYK MA; SERTH J; BOKEMEYER C; MACHTENS S; MINSSEN A; BATHKE W; HARTMANN J; JONAS U
      THE PROGNOSTIC VALUE OF P53 FOR LONG-TERM AND RECURRENCE-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY

      European journal of cancer
    70. HARTMANN JT; SCHMOLL E; BOKEMEYER C; FETY R; LUCAS C; GIROUX B; SCHMOLL HJ
      PHASE-I PHARMACOLOGICAL STUDY OF INTRAARTERIALLY INFUSED FOTEMUSTINE FOR COLORECTAL LIVER METASTASES

      European journal of cancer
    71. HARTMANN JT; HARSTRICK A; DAIKELER T; KOLLMANNSBERGER C; MULLER C; SEEBER S; KANZ L; BOKEMEYER C
      PHASE-II STUDY OF CONTINUOUS 120 H INFUSION OF MITOMYCIN-C AS SALVAGECHEMOTHERAPY IN PATIENTS WITH PROGRESSIVE OR RAPIDLY RECURRENT COLORECTAL-CANCER

      Anti-cancer drugs
    72. PONT J; BOKEMEYER C
      SALVAGE TREATMENT FOR GERM-CELL CANCER AFTER FAILED HIGH-DOSE THERAPY- RESPONSE

      Annals of oncology
    73. KOLLMANNSBERGER C; QUIETZCH D; CLEMENS M; LAMPE C; LINGENFELSER T; HARTMANN JT; KANZ L; BOKEMEYER C
      A PHASE-II TRIAL OF PACLITAXEL, CISPLATIN, AND WEEKLY 24 H INFUSION OF 5-FLUOROURACIL (5-FU) FOLINIC ACID (FA) IN PATIENTS (PTS) WITH ADVANCED GASTRIC-CANCER/

      Annals of oncology
    74. HARTMANN JT; NICHOLS CR; DROZ JP; HORWICH A; GERL A; FOSSA SD; BEYER J; PONT J; SCHMOLL HJ; BOKEMEYER C
      EXTRAGONADAL GERM-CELL TUMORS (EGGCT) AND HEMATOLOGIC DISORDERS - INCIDENCE AND OUTCOME FROM AN INTERNATIONAL DATABASE

      Annals of oncology
    75. KOLLMANNSBERGER C; BOYER J; DROZ JP; HARSTRICK A; HARTMANN JT; BIRON P; FLECHON A; SCHOFFSKI P; KUCZYK M; SCHMOLL HJ; KANZ L; BOKEMEYER C
      SECONDARY LEUKEMIA FOLLOWING HIGH CUMULATIVE DOSES OF ETOPOSIDE IN PATIENTS TREATED FOR ADVANCED GERM-CELL TUMORS

      Journal of clinical oncology
    76. BOKEMEYER C; HARTMANN JT; KUCZYK MA; TRUSS MC; KOLLMANNSBERGER C; BEYER J; JONAS U; KANZ L
      RECENT STRATEGIES FOR THE USE OF PACLITAXEL IN THE TREATMENT OF UROLOGICAL MALIGNANCIES

      World journal of urology
    77. HARTMANN JT; ALBERS P; CLEMM C; SOUCHON R; WEISSBACH L; BAMBERG M; BOKEMEYER C
      REGISTER STUDY FOR THE TREATMENT OF BRAIN METASTASES OF MALIGNANT TESTICULAR-TUMORS

      Onkologie
    78. MACHTENS S; BOKEMEYER C; SERTH J; JONAS U; KUCZYK MA
      ALTERATION OF THE P53 TUMOR-SUPPRESSOR GENE IN PROSTATE-CANCER - ANALYTICAL APPROACHES AND CLINICAL IMPLICATIONS

      Onkologie
    79. BOKEMEYER C; HARSTRICK A; BEYER J; METZNER B; RUTHER U; HARTMANN JT; HOLSTEIN K; DERIGS HG; DEWIT R; CASPER J; SCHOFFSKI P; KUHRER I; ILLIGER HJ; KEMPF B; REICHLE A; FOLLER A; HOSSFELD DK; FISCHER JT; BERDEL W; GERHARTZ H; KIRCHNER H; PFLUGER K; OSTERMANN H; KANZ L; SCHMOLL HJ
      FIRST-LINE HIGH-DOSE CHEMOTHERAPY FOR POOR-RISK METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS

      Onkologie
    80. Weissbach, L; Diehl, A; Bokemeyer, C
      Nonseminomatous testicular cancers in clinical stage IIA/B: Primary chemotherapy or primary lymphadenectomy?

      ONKOLOGIE
    81. Bokemeyer, C; Kollmannsberger, C; Kanz, L
      The potential role of topotecan in the treatment of pediatric and adult soft-tissue sarcomas

      ONKOLOGIE
    82. KUCZYK MA; KOHN G; HOFNER K; MACHTENS S; BOKEMEYER C; STIEF CG; TRUSS MC; SCHAFERS HJ; HARTMANN JT; JONAS U
      PROGNOSTIC VALUE OF INTRACAVAL NEOPLASTIC EXTENSION FOR PATIENTS WITHRENAL-CELL CANCER

      Der Urologe
    83. Jakob, A; Kollmannsberger, C; Kanz, L; Bokemeyer, C
      Late toxicity after treatment for testicular germ cell cancer

      UROLOGE-AUSGABE A
    84. BEYER J; KRAMAR A; MANDANAS R; LINKESCH W; GREINIX A; DROZ JP; PICO JL; DIEHL A; BOKEMEYER C; SCHMOLL HJ; NICHOLS CR; EINHORN LH; SIEGERT W
      PROGNOSTIC FACTORS FOR HIGH-DOSE CHEMOTHERAPY (HDCT) AS SALVAGE TREATMENT IN GERM-CELL TUMORS (GCT)

      Bone marrow transplantation
    85. HARTMANN JT; ALBERS P; CLEMM C; SOUCHON R; WEISSBACH L; BAMBERG M; BOKEMEYER C
      REGISTER STUDY OF PATIENTS WITH CNS METASTASES FROM TESTICULAR GERM-CELL CANCER

      Strahlentherapie und Onkologie
    86. KOLLMANNSBERGER C; HARTMANN JT; KANZ L; BOKEMEYER C
      RISK OF SECONDARY MYELOID-LEUKEMIA AND MYELODYSPLASTIC SYNDROME FOLLOWING STANDARD-DOSE CHEMOTHERAPY OR HIGH-DOSE CHEMOTHERAPY WITH STEM-CELL SUPPORT IN PATIENTS WITH POTENTIALLY CURABLE MALIGNANCIES

      Journal of cancer research and clinical oncology
    87. DOHMEN BM; BOKEMEYER C; OECHSLE K; LIETZENMAYER R; PFANNENBERG AC; BARES R
      PROGNOSTIC VALUE OF FDG-PET PERFORMED BEFORE HIGH-DOSE CHEMOTHERAPY IN GERM-CELL CANCER

      The Journal of nuclear medicine
    88. DOHMEN BM; BOKEMEYER C; OECHSLE K; LIETZENMAYER R; PFANNBERG AC; BARES R
      ACCURACY OF FDG-PET IN CLASSIFICATION OF RESIDUAL TUMOR MASSES AFTER CHEMOTHERAPY OF GERM-CELL CANCER

      The Journal of nuclear medicine
    89. BOKEMEYER C; HARSTRICK A; BEYER J; METZNER B; RUTHER U; HARTMANN JT; HOLSTEIN K; DERIGS HG; DEWIT R; CASPER J; SCHOFFSKI P; KUHRER I; ILLIGER HJ; KEMPF B; REICHLE A; FOLLER A; HOSSFELD DK; FISCHER JT; BERDEL WE; GERHARTZ HH; KIRCHNER H; PFLUGER KH; OSTERMANN H; KANZ L; SCHMOLL HJ
      THE USE OF DOSE-INTENSIFIED CHEMOTHERAPY IN THE TREATMENT OF METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS

      Seminars in oncology
    90. PFANNENBERG AC; DOHMEN BM; BOKEMEYER C
      PROGNOSTIC VALUE OF FDG-PET BEFORE HIGH-DOSE (HD) CHEMOTHERAPY (CTX) IN METASTATIC GERM-CELL TUMORS (GCT) - CORRELATION WITH CT AND MRI

      Radiology
    91. PFANNENBERG AC; DOHMEN BM; BOKEMEYER C
      PROGNOSTIC VALUE OF FDG-PET IN CLASSIFICATION OF RESIDUAL TUMORS AFTER HIGH-DOSE (HD) CHEMOTHERAPY (CTX) OF METASTATIC GERM-CELL TUMORS (GCT)

      Radiology
    92. HARTMANN JT; KOHNE CH; SCHMOLL HJ; DAIKELER T; KANZ L; BOKEMEYER C
      IS CONTINUOUS 24-HOUR INFUSION OF 5-FLUOROURACIL PLUS HIGH-DOSE FOLINIC ACID EFFECTIVE IN PATIENTS WITH PROGRESSIVE OR RECURRENT COLORECTAL-CANCER - A PHASE-II STUDY

      Oncology
    93. BOKEMEYER C
      CURRENT TRENDS IN CHEMOTHERAPY FOR METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS

      Oncology
    94. KUCZYK M; SERTH J; MACHTENS S; BOKEMEYER C; BATHKE W; STIEF EC; JONAS U
      EXPRESSION OF E-CADHERIN IN PRIMARY PROSTATE-CANCER - CORRELATION WITH CLINICAL-FEATURES

      British Journal of Urology
    95. BOKEMEYER C; BERGER CC; HARTMANN JT; KOLLMANNSBERGER C; SCHMOLL HJ; KUCZYK MA; KANZ L
      ANALYSIS OF RISK-FACTORS FOR CISPLATIN-INDUCED OTOTOXICITY IN PATIENTS WITH TESTICULAR CANCER

      British Journal of Cancer
    96. Machtens, S; Kuczyk, M; Serth, J; Bokemeyer, C; Macheel, I; Jetscho, I; Hradil, K; Hermann, R; Hartmann, J; Thon, WF; Jonas, U
      Prognostic significance of cell cycle-associated genes p27(Kipf) and p21(WAF/Cip) for muscle-invasive carcinoma

      AKTUELLE UROLOGIE
    97. Bokemeyer, C; Harstrick, A; Beyer, J; Metzner, B; Ruther, U; Hartmann, JT; Holstein, K; Derig, HG; De Wit, R; Casper, J; Schoffski, P; Kuhrer, I; Illiger, HJ; Kempf, B; Reichle, A; Foller, A; Hossfeld, DK; Fischer, JT; Berdel, WE; Gerhartz, HH; Kirchner, H; Pfluger, KH; Ostermann, H; Kanz, L; Schmoll, HJ
      The use of intensive chemotherapy for non-seminomatous testicular germ cell tumors

      EUROCANCER 98
    98. DAIKELER T; MAAS K; WEISS B; HARTMANN JT; KNOBLOCH A; ARNING M; KANZ L; BOKEMEYER C
      THE INFLUENCE OF GEMCITABINE ON THE CD4 CD8 RATIO IN PATIENTS WITH SOLID TUMORS/

      Oncology Reports
    99. HARTMANN JT; SCHMOLL E; BOKEMEYER C; FETY R; LUCAS C; DAGAY L; SCHMOLL HJ
      HEPATIC ARTERIAL INFUSION OF THE NITROSOUREA DERIVATE FOTEMUSTINE FORTHE TREATMENT OF LIVER METASTASES FROM COLORECTAL-CARCINOMA

      Oncology Reports
    100. HARTMANN JT; CANDELARIA M; KUCZYK MA; SCHMOLL HJ; BOKEMEYER C
      COMPARISON OF HISTOLOGICAL RESULTS FROM THE RESECTION OF RESIDUAL MASSES AT DIFFERENT SITES AFTER CHEMOTHERAPY FOR METASTATIC NONSEMINOMATOUS GERM-CELL TUMORS

      European journal of cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/10/20 alle ore 05:13:47